The NLRP3 inflammasome is a potential mechanism and therapeutic target for perioperative neurocognitive disorders

被引:9
|
作者
Li, Jiayue [1 ]
Li, Li [1 ]
He, Jiannan [1 ]
Xu, Jianhong [1 ]
Bao, Fangping [1 ,2 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 4, Int Inst Med, Sch Med,Dept Anesthesiol, Yiwu, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Dept Anesthesiol, Sch Med, Hangzhou, Peoples R China
来源
关键词
perioperative neurocognitive disorders; pyroptosis; NLRP3; inflammasomes; posttranscriptional modifications; targeted protein degradation; nanotechnology; POSTOPERATIVE COGNITIVE DYSFUNCTION; NF-KAPPA-B; MOBILITY GROUP BOX-1; RISK-FACTORS; GASDERMIN D; ACTIVATION; INHIBITION; IMPAIRMENT; PYROPTOSIS; SURGERY;
D O I
10.3389/fnagi.2022.1072003
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Perioperative neurocognitive disorders (PNDs) are frequent complications associated with cognitive impairment during the perioperative period, including acute postoperative delirium and long-lasting postoperative cognitive dysfunction. There are some risk factors for PNDs, such as age, surgical trauma, anesthetics, and the health of the patient, but the underlying mechanism has not been fully elucidated. Pyroptosis is a form of programmed cell death that is mediated by the gasdermin protein and is involved in cognitive dysfunction disorders. The canonical pathway induced by nucleotide oligomerization domain (NOD)-, leucine-rich repeat (LRR)- and pyrin domain-containing protein 3 (NLRP3) inflammasomes contributes to PNDs, which suggests that targeting NLRP3 inflammasomes may be an effective strategy for the treatment of PNDs. Therefore, inhibiting upstream activators and blocking the assembly of the NLRP3 inflammasome may attenuate PNDs. The present review summarizes recent studies and systematically describes the pathogenesis of NLRP3 activation and regulation and potential therapeutics targeting NLRP3 inflammasomes in PNDs patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Therapeutic Potential of Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis
    Jie Gao
    Hongliang Zhang
    Yanyan Yang
    Jinhui Tao
    Inflammation, 2023, 46 : 835 - 852
  • [32] The NLRP3 Inflammasome: Role and Therapeutic Potential in Pain Treatment
    Starobova, Hana
    Nadar, Evelyn Israel
    Vetter, Irina
    FRONTIERS IN PHYSIOLOGY, 2020, 11
  • [33] The NLRP3 Inflammasome as a Pharmacological Target
    Marchetti, Carlo
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2019, 74 (04) : 285 - 296
  • [34] NLRP3 inflammasome activation By 17β-estradiol is a potential therapeutic target in hepatocellular carcinoma treatment
    Awwad, Sara F.
    Assaf, Raymonde H.
    Emam, Ahmed A.
    Fouad, Amgad A.
    Arafa, Lamiaa F.
    El-Hanafy, Aya A.
    MEDICAL ONCOLOGY, 2023, 40 (03)
  • [35] NLRP3 inflammasome activation By 17β-estradiol is a potential therapeutic target in hepatocellular carcinoma treatment
    Sara F. Awwad
    Raymonde H. Assaf
    Ahmed A. Emam
    Amgad A. Fouad
    Lamiaa F. Arafa
    Aya A. El-Hanafy
    Medical Oncology, 40
  • [36] TI: NLRP3 Inflammasome-Dependent Pyroptosis in CNS Trauma: A Potential Therapeutic Target
    Zhou, Conghui
    Zheng, Jinfeng
    Fan, Yunpeng
    Wu, Junsong
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [37] NLRP3 inflammasome as a novel therapeutic target for Alzheimer's disease
    Zhang, Yun
    Dong, Zhifang
    Song, Weihong
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [38] NLRP3 inflammasome as a novel therapeutic target for Alzheimer’s disease
    Yun Zhang
    Zhifang Dong
    Weihong Song
    Signal Transduction and Targeted Therapy, 5
  • [39] The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout
    Szekanecz, Zoltan
    Szamosi, Szilvia
    Kovacs, Gergo E.
    Kocsis, Elek
    Benko, Szilvia
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2019, 670 : 82 - 93
  • [40] NLRP3 Inflammasome as a Therapeutic Target for Atherosclerosis: A Focus on Potassium Outflow
    Jin, Yi-Jing
    An, Zhuo-Yu
    Sun, Zhi-Xuan
    Liu, Xin-Chen
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (08)